Cargando…

Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism

[Image: see text] Caffeine, the most consumed psychoactive substance worldwide, may have beneficial effects on Parkinson’s disease (PD) therapy. The mechanism by which caffeine contributes to its antiparkinsonian effects by acting as either an adenosine A(2A) receptor (A(2A)R) neutral antagonist or...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Dueñas, Víctor, Gómez-Soler, Maricel, López-Cano, Marc, Taura, Jaume J., Ledent, Catherine, Watanabe, Masahiko, Jacobson, Kenneth A., Vilardaga, Jean-Pierre, Ciruela, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245165/
https://www.ncbi.nlm.nih.gov/pubmed/25268872
http://dx.doi.org/10.1021/cb5005383
_version_ 1782346323671908352
author Fernández-Dueñas, Víctor
Gómez-Soler, Maricel
López-Cano, Marc
Taura, Jaume J.
Ledent, Catherine
Watanabe, Masahiko
Jacobson, Kenneth A.
Vilardaga, Jean-Pierre
Ciruela, Francisco
author_facet Fernández-Dueñas, Víctor
Gómez-Soler, Maricel
López-Cano, Marc
Taura, Jaume J.
Ledent, Catherine
Watanabe, Masahiko
Jacobson, Kenneth A.
Vilardaga, Jean-Pierre
Ciruela, Francisco
author_sort Fernández-Dueñas, Víctor
collection PubMed
description [Image: see text] Caffeine, the most consumed psychoactive substance worldwide, may have beneficial effects on Parkinson’s disease (PD) therapy. The mechanism by which caffeine contributes to its antiparkinsonian effects by acting as either an adenosine A(2A) receptor (A(2A)R) neutral antagonist or an inverse agonist is unresolved. Here we show that caffeine is an A(2A)R inverse agonist in cell-based functional studies and in experimental parkinsonism. Thus, we observed that caffeine triggers a distinct mode, opposite to A(2A)R agonist, of the receptor’s activation switch leading to suppression of its spontaneous activity. These inverse agonist-related effects were also determined in the striatum of a mouse model of PD, correlating well with increased caffeine-mediated motor effects. Overall, caffeine A(2A)R inverse agonism may be behind some of the well-known physiological effects of this substance both in health and disease. This information might have a critical mechanistic impact for PD pharmacotherapeutic design.
format Online
Article
Text
id pubmed-4245165
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42451652015-09-30 Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism Fernández-Dueñas, Víctor Gómez-Soler, Maricel López-Cano, Marc Taura, Jaume J. Ledent, Catherine Watanabe, Masahiko Jacobson, Kenneth A. Vilardaga, Jean-Pierre Ciruela, Francisco ACS Chem Biol [Image: see text] Caffeine, the most consumed psychoactive substance worldwide, may have beneficial effects on Parkinson’s disease (PD) therapy. The mechanism by which caffeine contributes to its antiparkinsonian effects by acting as either an adenosine A(2A) receptor (A(2A)R) neutral antagonist or an inverse agonist is unresolved. Here we show that caffeine is an A(2A)R inverse agonist in cell-based functional studies and in experimental parkinsonism. Thus, we observed that caffeine triggers a distinct mode, opposite to A(2A)R agonist, of the receptor’s activation switch leading to suppression of its spontaneous activity. These inverse agonist-related effects were also determined in the striatum of a mouse model of PD, correlating well with increased caffeine-mediated motor effects. Overall, caffeine A(2A)R inverse agonism may be behind some of the well-known physiological effects of this substance both in health and disease. This information might have a critical mechanistic impact for PD pharmacotherapeutic design. American Chemical Society 2014-09-30 2014-11-21 /pmc/articles/PMC4245165/ /pubmed/25268872 http://dx.doi.org/10.1021/cb5005383 Text en Copyright © 2014 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Fernández-Dueñas, Víctor
Gómez-Soler, Maricel
López-Cano, Marc
Taura, Jaume J.
Ledent, Catherine
Watanabe, Masahiko
Jacobson, Kenneth A.
Vilardaga, Jean-Pierre
Ciruela, Francisco
Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title_full Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title_fullStr Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title_full_unstemmed Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title_short Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
title_sort uncovering caffeine’s adenosine a(2a) receptor inverse agonism in experimental parkinsonism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245165/
https://www.ncbi.nlm.nih.gov/pubmed/25268872
http://dx.doi.org/10.1021/cb5005383
work_keys_str_mv AT fernandezduenasvictor uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT gomezsolermaricel uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT lopezcanomarc uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT taurajaumej uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT ledentcatherine uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT watanabemasahiko uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT jacobsonkennetha uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT vilardagajeanpierre uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism
AT ciruelafrancisco uncoveringcaffeinesadenosinea2areceptorinverseagonisminexperimentalparkinsonism